abrdn plc Purchases 13,979 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

abrdn plc boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 32.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,033 shares of the company's stock after buying an additional 13,979 shares during the quarter. abrdn plc owned approximately 0.20% of Krystal Biotech worth $8,935,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Summit Trail Advisors LLC acquired a new position in Krystal Biotech during the third quarter worth approximately $1,893,000. Swiss National Bank boosted its holdings in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after acquiring an additional 2,900 shares during the period. Shaker Investments LLC OH bought a new stake in shares of Krystal Biotech during the third quarter worth approximately $532,000. Citigroup Inc. boosted its holdings in shares of Krystal Biotech by 65.4% during the third quarter. Citigroup Inc. now owns 35,084 shares of the company's stock worth $6,386,000 after acquiring an additional 13,874 shares during the period. Finally, Janney Montgomery Scott LLC boosted its holdings in shares of Krystal Biotech by 42.0% during the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock worth $8,239,000 after acquiring an additional 15,545 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 14.10% of the company's stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup boosted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Finally, Chardan Capital reiterated a "buy" rating and issued a $212.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and a consensus target price of $206.67.

Krystal Biotech Stock Up 0.9 %

Shares of KRYS stock traded up $1.40 during trading hours on Wednesday, reaching $151.32. The company's stock had a trading volume of 288,068 shares, compared to its average volume of 237,710. The firm's 50 day simple moving average is $160.45 and its 200-day simple moving average is $176.84. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of 85.49 and a beta of 0.84. Krystal Biotech, Inc. has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).